Note: Ingredients listed on restricted chemical lists
EC/CAS
200-679-5/68-12-2
Name of the chemical
Dimethyl formamide; N,N-dimethylformamide (DMFa)
Concentration
>=50-<70 616-001-
General Information
Version
8.2
Revision date
2024-01-09
Product name
NBT, SOLUTION
REACH No
This
1.2.2. Uses advised against
For R&D use only. Not for pharmaceutical, household or other uses
Emergency telephone
+44 (0)870 8200418
Icons in SDS
Company Information
company name
Merck Life Science UK Limited
e-mail address of the competent person responsible for the Safety Data Sheet
TechnicalService@merckgroup.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H315, H319, H332, H360D
Hazard statements
Code
Statements
H315
Causes skin irritation
Section 2
SECTION 2: Hazards identification
2.2 Label elements
Labelling
Signal word
Danger
Hazard statements
H315 Causes skin irritation. H319 Causes serious eye irritation. H332 Harmful if inhaled. H360D May damage the unborn child. Restricted to professional users.
Precautionary statements
P201 Obtain special instructions before use. P261 Avoid breathing mist or vapors. P264 Wash skin thoroughly after handling. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection. P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell. P308 + P313 IF exposed or concerned: Get medical advice/ attention.
Supplemental label elements
none
2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
ECOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
TOXICOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
